BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 3,180,000 shares, a decline of 17.0% from the February 13th total of 3,830,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 7.4% of the shares of the company are sold short.

Institutional Trading of BioAtla

Several hedge funds and other institutional investors have recently bought and sold shares of BCAB. Magnus Financial Group LLC acquired a new position in shares of BioAtla in the 4th quarter valued at approximately $28,000. Two Sigma Investments LP raised its position in shares of BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after buying an additional 61,725 shares in the last quarter. Jane Street Group LLC raised its position in shares of BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after buying an additional 100,204 shares in the last quarter. Norges Bank acquired a new position in shares of BioAtla in the 4th quarter valued at approximately $230,000. Finally, XTX Topco Ltd raised its position in shares of BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after buying an additional 10,384 shares in the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Stock Up 4.9 %

Shares of BioAtla stock opened at $0.36 on Tuesday. BioAtla has a twelve month low of $0.24 and a twelve month high of $4.02. The company has a 50-day simple moving average of $0.43 and a two-hundred day simple moving average of $1.21. The stock has a market capitalization of $17.43 million, a price-to-earnings ratio of -0.21 and a beta of 1.19.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.